로딩 중…
지수 로딩 중…
BioNote, Inc.
377740· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,515-2.48%
2026-10-15
Financials
Valuation Metrics
BioNote, Inc.'s Market Cap is ₩4600B. At end of 2025 it was ₩5573B. Ranked #470 of 2,414 in KR market (top 19%), #299 of 781 on KOSPI (top 38%), #50 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 460.02B KRW | KR#470/2,414 Sec#50/231 |
| Revenue | 126.41B KRW | KR#1,277/2,414 Sec#78/231 |
| Net Income | -125.69B KRW | KR—/2,414 Sec—/231 |
| Total Assets | 1.56T KRW | KR#363/2,414 Sec#15/231 |
| Net Assets | 1.51T KRW | KR#220/2,414 Sec#9/231 |
| Employees | 313 | KR#768/2,414 Sec#67/231 |
| Value | ||
| P/B | 0.30x | KR#389/2,414 Sec#12/231 |
| P/S | 3.64x | KR#2,077/2,414 Sec#131/231 |
| EV/EBITDA | 21.61x | KR#1,078/2,414 Sec#65/231 |
| FCF Yield | 1.36% | KR#1,113/2,414 Sec#79/231 |
| Profitability | ||
| ROE | -8.32% | KR#1,900/2,414 Sec#140/231 |
| ROA | -8.08% | KR#2,054/2,414 Sec#152/231 |
| Op. Margin | 16.19% | KR#261/2,414 Sec#25/231 |
| Revenue Growth | 12.82% | KR#766/2,414 Sec#74/231 |
| Earnings Growth | -204.60% | KR#1,239/2,414 Sec#84/231 |
| Financial Health | ||
| Debt Ratio | 2.95% | KR#14/2,414 Sec#6/231 |
| Total Debt | 0 KRW | KR—/2,414 Sec—/231 |
| FCF | 6.27B KRW | KR#845/2,414 Sec#57/231 |
| Cash | 17.87B KRW | KR#1,310/2,414 Sec#102/231 |
| Current Ratio | 18.53x | KR#33/2,414 Sec#14/231 |
| Net Debt/EBITDA | -0.87x | KR#408/2,414 Sec#23/231 |
| Dividend | ||
| Div. Yield | 5.02% | KR#312/2,414 Sec#11/231 |
| Div. Growth | 14.00% | KR#533/2,414 Sec#29/231 |
| Performance | ||
| 1Y Return | -21.75% | KR#1,219/2,414 Sec#86/231 |
| 1M Return | -4.24% | KR#917/2,414 Sec#83/231 |
| From 52W High | -27.88% | KR#379/2,414 Sec#24/231 |
| 1Y MDD | -29.94% | KR#251/2,414 Sec#16/231 |
| Trading | ||
| Volume | 99,504 shares | KR#938/2,414 Sec#93/231 |
| Trading Value | 446.3M KRW | KR#1,110/2,414 Sec#119/231 |
| Foreign Own. | 0.54% | KR#2,190/2,414 Sec#210/231 |
| Per Share | ||
| EPS | -1,234 KRW | KR—/2,414 Sec—/231 |
| BPS | 14,833 KRW | KR#708/2,414 Sec#46/231 |
Company Info
Bionote, established in 2003 and listed on the KOSPI market in 2022, specializes in animal diagnostic products and bio-content. Utilizing its unique recombinant antigen and antibody manufacturing technology, it produces and distributes diverse diagnostic products and bio-content across over 80 countries. The company is expanding its business into molecular and biochemical diagnostics. It aims to increase global market share by launching fully automated point-of-care diagnostic devices.